Takeda’s Febuxostat Finally Gets U.S. Advisory Panel Review
This article was originally published in PharmAsia News
Takeda North America's long-delayed investigational gout drug febuxostat, previously the subject of two "approvable" letters, will be reviewed by the U.S. FDA Arthritis Drugs Advisory Committee on Nov. 24
You may also be interested in...
Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott
SHANGHAI - Teijin Pharma will launch xanthine oxidase inhibitor TMX67, its novel gout drug, in Europe, the company announced Feb. 25.The Tokyo-based company received a positive recommendation Feb. 21 from the European Medicines Agency's Committee for Medicinal Products for Human Use
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).